Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

When HIV was first identified

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

On 5 June 1981 the CDC published a short report about five young men in Los Angeles with a pneumonia that normally only appears in people whose immune systems have failed.

The report ran to a page and a half. It is the beginning of the recorded history of AIDS.

Related pages: HIV

The bottom line

What we know
  • The first report of what became AIDS was published on 5 June 1981.
  • The virus was isolated at the Pasteur Institute in 1983.
  • The name HIV was agreed in 1986, replacing several competing names.
  • Effective combination treatment arrived in 1996 and transformed survival.
What is still open
  • How long the virus had been present in North America and Europe before 1981.
  • How many early deaths were recorded as something else entirely.

The story, step by step

  1. 1. 1981 ()
  2. 2. 1982 ()
  3. 3. 1983 to 1984 ()
  4. 4. 1986 to 1995 ()
  5. 5. 1996 to now ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Five men, and a pneumonia that should not have been there

Review of many studies

What happens

The first signal was not a new illness. It was an old illness in the wrong people.

What the research shows

  • The CDC's Morbidity and Mortality Weekly Report described five previously healthy young men in Los Angeles with Pneumocystis carinii pneumonia.
  • That infection was essentially unheard of in people with working immune systems.
  • Within weeks, reports arrived of Kaposi sarcoma, a rare skin cancer, in young men in New York and California.
  • An alert pharmacist noticing unusual orders for pentamidine, the drug used for that pneumonia, helped bring the cluster to attention.

Why it matters

The outbreak was caught because clinicians noticed that the ordinary explanation did not fit. That is how most new diseases are found.

What's still uncertain

  • By the time the first report appeared, the virus had been spreading for decades and was already present on several continents.

Read more

Next: 1982

Part 2 of 5

Getting the name right, after getting it wrong

Review of many studies

What happens

The early names reflected early assumptions, and the assumptions were wrong.

What the research shows

  • The condition was informally called GRID, for gay-related immune deficiency, and in the press the slur that followed from it.
  • Cases in people with haemophilia, in people who injected drugs, in recipients of blood transfusions and in infants made the name untenable.
  • In September 1982 the CDC adopted the term acquired immune deficiency syndrome, AIDS, and published a case definition.
  • The blood-product cases also pointed strongly to an infectious agent carried in blood.

Why it matters

The early misnaming shaped a decade of stigma and public-health failure, and some of it has never fully gone away.

What's still uncertain

  • The outbreak was recognized in the United States first largely because of its surveillance system, not because it began there.

Read more

Next: 1983 to 1984

Part 3 of 5

Isolated in Paris, contested in Washington

Review of many studies

What happens

The virus itself was found quickly, by historical standards. Credit for finding it took much longer.

What the research shows

  • In 1983 Francoise Barre-Sinoussi and Luc Montagnier at the Pasteur Institute isolated a retrovirus from a patient's lymph node and called it LAV.
  • In 1984 Robert Gallo's laboratory in the United States announced a virus it called HTLV-III and declared it the cause of AIDS.
  • The two viruses turned out to be essentially the same, and the dispute over priority, and over blood-test patent royalties, ran for years.
  • Barre-Sinoussi and Montagnier received the Nobel Prize in Physiology or Medicine in 2008.

Why it matters

A blood test followed in 1985, which made it possible to protect the blood supply. That was the first thing the discovery actually changed.

What's still uncertain

  • The scientific dispute was eventually settled by a political agreement between two governments as much as by the evidence.

Read more

Next: 1986 to 1995

Part 4 of 5

A name, a drug, and a decade of losing

Review of many studies

What happens

The middle years were the worst ones.

What the research shows

  • In 1986 an international committee settled on human immunodeficiency virus, HIV, retiring LAV, HTLV-III and ARV.
  • AZT was approved in 1987 after an unusually fast trial. It extended life by months and then failed as resistance emerged.
  • Through the late 1980s and early 1990s, an AIDS diagnosis in high-income countries remained close to a death sentence.
  • Activist organizations, notably ACT UP, forced changes in how trials were designed and how quickly drugs could be reviewed, changes that outlived the crisis and altered drug regulation generally.

Why it matters

The most lasting legacy of this period is not a drug. It is the idea that patients have a legitimate place in deciding how research is done.

What's still uncertain

  • How much AZT monotherapy helped or harmed, at the doses first used, is still argued over.

Read more

Next: 1996 to now

Part 5 of 5

The year the graphs turned

Review of many studies

What happens

At the 1996 international AIDS conference in Vancouver, combination antiretroviral therapy was presented. Death rates in treated populations fell within a year.

What the research shows

  • Combining three drugs from different classes suppressed the virus far below what any single drug could manage.
  • Deaths from AIDS in countries with access to the drugs dropped steeply and quickly.
  • Access was the next fight: treatment reached most of the world only after a long campaign over patents and pricing in the 2000s.
  • Since then: single-pill regimens, PrEP in 2012, the U=U evidence in the late 2010s, and twice-yearly injectable prevention approved in 2025.

Why it matters

The science moved faster than access did, and that gap, rather than the biology, is what still shapes who dies of HIV today.

What's still uncertain

  • Millions of people worldwide still do not have reliable access to treatment, and funding for global HIV programmes remains uncertain.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.